Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jun 20:8:2050313X20934708.
doi: 10.1177/2050313X20934708. eCollection 2020.

Intravenous N-acetylcysteine in severe cutaneous drug reaction treatment: A case series

Affiliations
Case Reports

Intravenous N-acetylcysteine in severe cutaneous drug reaction treatment: A case series

Md Jahidul Hasan et al. SAGE Open Med Case Rep. .

Abstract

Drug-induced serious adverse reaction is an unpleasant event with high rate of mortality. Stevens-Johnson Syndrome and toxic epidermal necrolysis are most common among the serious adverse drug reactions. There is no selective drug therapy for the management of serious adverse drug reactions-associated mucocutaneous blisters. The use of N-acetylcysteine in the treatment of mucocutaneous blisters has limited evidence worldwide. Three cases of toxic epidermal necrolysis or Stevens-Johnson Syndrome-associated mucocutaneous blisters are presented in this study where intravenous N-acetylcysteine (600 mg, every 8 h) was given in early hospitalization hours for the treatment of mucocutaneous fluid-filled blisters. Here, one patient with toxic epidermal necrolysis received intravenous immunoglobulin along with intravenous N-acetylcysteine and the other two patients (toxic epidermal necrolysis/Stevens-Johnson Syndrome) received only N-acetylcysteine intravenously. In response, mucocutaneous fluid-filled blisters stopped progressing within 48 h and were healed within 2 weeks of admission in the intensive care unit. Thus, intravenous N-acetylcysteine with or without having intravenous immunoglobulin in the treatment of serious adverse drug reactions-associated mucocutaneous blisters may be an effective therapeutic option for better clinical outcome.

Keywords: N-acetylcysteine; Serious adverse drug reactions; Stevens–Johnson syndrome; mucocutaneous blister; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(a) Mucocutaneous blisters at the time of admission in ICU. (b) Healing of fluid-filled blisters after 48 h of admission. (c) Complete re-epithelialization of the lesions on 12th day of admission.
Figure 2.
Figure 2.
(a) Mucocutaneous blisters at the time of admission in ICU. (b) Healed blisters after 48 h of admission. (c) Day 9 of admission with complete re-epithelialization of the lesions.
Figure 3.
Figure 3.
(a) Mucocutaneous blisters at the time of admission in ICU. (b) Healed blisters after 48 h of admission. (c) Day 4 of admission with suppressed skin lesions.

References

    1. Gautron S, Wentzell J, Kanji S, et al. Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting. Can J Hosp Pharm 2018; 71(5): 316–323. - PMC - PubMed
    1. Nguyen KD, Tran TN, Nguyen MT, et al. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: a subgroup approach to disproportionality analysis. J Clin Pharm Ther 2019; 44(1): 69–77. - PubMed
    1. Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: a north Indian perspective. Int J Appl Basic Med Res 2011; 1(1): 50–53. - PMC - PubMed
    1. Mokhtari V, Afsharian P, Shahhoseini M, et al. A review on various uses of N-acetyl cysteine. Cell J 2017; 19(1): 11–17. - PMC - PubMed
    1. Saavedra C, Cárdenas P, Castellanos H, et al. Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine. Case Reports Immunol 2012; 2012: 931528. - PMC - PubMed

Publication types

LinkOut - more resources